Rizzo_et_al_Revised_Supplementary_material – Supplemental material for Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis

Supplemental material, Rizzo_et_al_Revised_Supplementary_material for Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis by Alessandro Rizzo, Margherita Nannini, Marco Novelli, Angela Dalia Ricci, Valerio Di Scioscio and Maria Abbondanza Pantaleo in Therapeutic Advances in Medical Oncology